CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosis

Cancer Prevention Research

Volumn 4, Issue 3, 2011, Pages 414-424

  Wiehle, Ronald ^a   Lantvit, Daniel ^b   Yamada, Tohru ^b   Christov, Konstantin ^b  

^a Repros Therapeutics Inc   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; ESTRADIOL; ESTROGEN RECEPTOR; METHYLNITROSOUREA; PLACEBO; PROGESTERONE RECEPTOR; TELAPRISTONE ACETATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENICITY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PELLET; ESTRADIOL BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; HORMONE RECEPTOR INTERACTION; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROTEIN EXPRESSION; RAT; STEROID RELEASE; TREATMENT DURATION; TUMOR CELL;

ANIMALS; APOPTOSIS; CARCINOGENS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MAMMARY NEOPLASMS, ANIMAL; METHYLNITROSOUREA; MODELS, BIOLOGICAL; NORPREGNADIENES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 79955839379     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0244     Document Type: Article

References (40)

1. Rossow JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33. (Pubitemid 34761611)
2. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53. (Pubitemid 37430077)
3. Rohan TE, Negassa A, Chlebowski RT, Lasser NL, McTiernan A, Schenken RS, et al. Estrogen plus progestin and risk of benign proliferative breast disease. Cancer Epidemiol Biomarker Prev 2008;17:2337-43.
4. Chabert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanism of action and clinical applications. Hum Reprod 2005;11:293-07.
5. Engman M, Skoog L, Soderquist G, Dannielson KG. The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum Reprod 2008;23:2072-9.
6. Bardon S, Vignon F, Montcourrier P, Rochefort H. Steroid receptor-mediated cytotoxicity of an antiestrogen and an anti-progestin in breast cancer cells. Cancer Res 1987;47:1441-8. (Pubitemid 17023221)
7. Michna H, Schneider MR, Nishino Y, Etreby MF. The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death. J Steroid Biochem 1989;34:447-53. (Pubitemid 20061827)
8. Neven P, van Gorp T, Deraedt K. A gene signature of loss of estrogen receptor (ER) function and oxidative stress links ER-positive breast tumors with an absent progesterone receptor and a poor prognosis. Breast Cancer Res 2008;10:109-13.
9. Frank DW, Kitron KT, Murchism TE, Quinlan WJ, Coleman ME, Gilbertson TJ, et al. Mammary tumors and serum hormones in the bitch treated with medroxyprogesterone acetate or progesterone for four years. Fertil Steril 1979;31:340-6. (Pubitemid 9125400)
10. Nagasawa H, Aoki M, Sakagami N, Ishida M. Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice. Cancer Res Treat 1988;12:59-66.
11. Bakker GH, Setyono-Han B, Henkelman MS, de Jong FH, Lamberts SW, van der Schoot P, et al. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors. Cancer Treat Rep 1987;71:1021-7. (Pubitemid 18002209)
12. Wiehle RD, Christov K, Mehta R. Antiprogestin suppresses growth of established tumors induced by 7,12-dimethylbenz(a)anthracene: comparison between RU486 and a new 21-substituted-19-nor-progestines. Oncol Rep 2007;18:167-74.
13. Lydon JP, Ge G, Kitrell FS, Medina D, O'Malley BW. Endocrine and antitumor effects of combined treatment with an anti-progestin and anti-estrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. Cancer Res 1999;59:4276-84.
14. Michna H, Schneider MR, Nishino Y, Etreby MF. Antitumor activity of the anti-progestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies. Breast Cancer Res Treat 1989;14:275-88. (Pubitemid 20053757)
15. Chatterton RT, Lydon JP, Mehta RG, Mateo ET, Pletz A, Jordan VC. Role of the progesterone receptor (PR) in susceptibility of mouse mammary gland to 7,12-dimethylbenz[a]anthracene-induced hormone-independent preneoplastic lesions in vitro. Cancer Lett 2002;188:47-52. (Pubitemid 35292328)
16. Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA, Klijn JGM. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing animal tumors. Endocrinol 1989;125:1593-8. (Pubitemid 19224015)
17. Machna H, Gehring S, Kühnel W, Nishino Y, Schneider MR. The antitumor potency of progesterone antagonists is due to their differentiation potential. J Steroid Biochem Mol Biol 1992;43:203-10.
18. Forby B, Wiley TS. Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Ann Clin Lab Sci 1998;28:360-9.
19. Gaddy VT, Barett JT, Delk JN, Kallab AM, Porter AG, Schoenlein PV. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor expressing antiestrogen resistant breast cancer cells. Clin Cancer Res 2004;10:5215-25. (Pubitemid 39099796)
20. Dressing GE, Lange CA. Integrated actions of progesterone receptor and cell cycle machinery regulate breast cancer cell proliferation. Steroids 2009;10:6613-7.
21. Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA, Klijn JG. Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J Steroid Biochem Mol Biol 1990;37:789-94.
22. Kettel LM, Murphy AA, Mortola AJ, Liu JH, Ulmann A, Yen SSC. Endocrine responses to long-term administration of the anti-progesterone RU486 in patients with pelvic endometriosis. Fertil Steril 1991;56:402-7.
23. Klijn JGM, Setyono-Han B, Foekens JA. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 2000:65:825-30.
24. Attardi B, Burgenson J, Hild S, Reel JR, Blye RP. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 2002;188:111-23. (Pubitemid 34242671)
25. Attardi B, Burgenson J, Hild SA, Reel JR. In vitro antiprogestational/ antiglucocorticoid activity and progestin and glucocorticoid receptor binding activity of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124 and mifepristone. J Steroid Biochem Mol Biol 2004;88:277-88.
26. Wiehle RDW, Goldberg J, Brodniewicz T, Jarus-Dziedzic K, Jabiry- Zieniewicz Z, et al., Effects of a new progesterone receptor modulator, CDB-4124, on fibroid size and uterine bleeding. US Obstet and Gynaecol 2008:3:17-20.
27. Spitz IM, Wiehle RD, van As A. Progesterone receptor modulators in the endometriosis: a new therapeutic option. In:Garcia-Velasco J, Rizk B, editors. Endometriosis: current management and future trends. New Delhi, India: Jaypee; 2009. p. 225-34.
28. Spitz IM. Clinical utility of progesterone receptor modulators and their effect in the endometrium. Curr Opin Obstet Gynecol 2009;21:318-24.
29. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006;314:1467-70. (Pubitemid 44871955)
30. Joffe OB, Zaino RJ, Mutter GL. Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator. Mod Pathol 2009;22:450-9
31. Christov K, Grubbs C, Shilkaitis A, Juliana MM, Lubet R. Short term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model. Clin Cancer Res 2007;13:5488-96. (Pubitemid 47510377)
32. Christov K, Shilkaitis A, Green A, Yao R, You M, et al. Tamoxifen selectively modulates the expression of cell cycle regulatory proteins in mammary tumors. Breast Cancer Res Treat 2003;77:253-64.
33. Chui X, Schiff R, Arpino G, et al. Biology of progesterone receptor loss in breast cancer and its implication for endocrine therapy. J Clin Oncol 2005;23:7221-35.
34. Lange CA, Sartoris CA, Adbel-Hafiz H, Spillman MA, Horwitz KB, Jacobsen BM. Progesterone receptor action: translating studies in breast cancer models to clinical insights. In:Bernstein LM, Santen RJ, editors. Innovative Endocrinology of Cancer.New York: Springer Science; 2008. p. 94-111.
35. Sutherland RL, Hall RE, Pang GY, Musgrove EA, Clarke CL. Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res 1988;48:5084-91.
36. Kester HA, Van Der Leede, Van Der Saag, Van Der Burg B. Novel progesterone target genes identified by an improved differential display technique suggest that progestin-induced growth inhibition of breast cancer cells coincides with enhancement of differentiation. J Biol Chem 1997;11:5032-43.
37. Fabre A, Fournier A, Masrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Progestagens use before menopause and breast cancer risk according to histology and hormone receptors. Cancer Epidem Biomarkers Prev 2008;17:2723-8.
38. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-65.
39. Graham JD, Mote PA, Salagame U, van Dijk JH, Balleine RL, Huschtscha LI, et al., DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinol 2009;150:3318-26.
40. Daniel AR, Lange CA. Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells. Proc Natl Acad Sci U S A 2009;106:14287-92.